Moderna, Inc. (MRNA)
Moderna Co-Founder Robert Langer Is A Billionaire Again As Shares Double In Value
Shares of Moderna rocketed by 156% to around $161 as of Wednesday morning, adding more than $100 in value to the stock after the firm announced results from its first-ever late-stage trial of an experimental melanoma vaccine. The vaccine, an mRNA-based shot combined with Merck's immunotherapy drug Keytruda, marked the first successful final-stage study for any mRNA-based cancer therapy after Moderna said the drug helped cut the recurrence of severe skin cancer and extended the time patients lived without their melanoma returning.
Moderna Stock Eyes Best Day Ever After Cancer Vaccine Breakthrough
Moderna Inc (NASDAQ:MRNA) is powering up the Nasdaq this morning, last seen126.5% higher to trade at $142.61.
Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rocketing higher Wednesday morning, with the stock up 93% to $121.76 in early Wednesday trading after the company and partner Merck (NYSE:MRK) announced that their Phase 3 melanoma trial met its primary endpoint.
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data
Moderna and Merck delivered positive news about their personalized skin-cancer vaccine Wednesday. Investors are buying their shares in droves.
Moderna's share price nearly doubles on hopes of cancer treatment breakthrough
Optimism about a potential breakthrough in personalised cancer treatment has sent shares in Moderna soaring by nearly 100%.
Moderna Shares Skyrocket 85% Toward Best Day Ever—On Success Of Cancer Drug Trial
This is a developing story.
Why is Moderna stock up 87% today during premarket trade?
Moderna MRNA shares surged in premarket trading on Wednesday after the company said its mRNA vaccine, when combined with Merck's Keytruda immunotherapy, delivered positive results in a late-stage trial for skin cancer. At one point, before the bell, the stock doubled, jumping more than 99% to $125.68, from Tuesday's close of $62.96, putting it on track for its highest level since 2024.
Why Moderna stock is rocketing today
Moderna (NASDAQ: MRNA) stock is rocketing in pre-market trading on Wednesday after the biotechnology company and its partner, Merck, reported positive Phase 3 results for their personalized mRNA-based cancer vaccine for melanoma.
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial. The combination regimen met the main study goal of significantly extending the time patients lived without their melanoma returning, compared with Keytruda alone, and also reduced the risk of the cancer spreading to distant parts of the body.
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.
This new kind of flu shot by Moderna has just been approved by the FDA
The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, said the manufacturer, Moderna.The shot, named mFlusiva, is intended for adults who are 50 and older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.While there already are multiple flu vaccine options in the U.S., including three specifically recommended for people age 65 or older, tens of thousands of Americans die from influenza every year and older adults are among the most vulnerable.Flu vaccines must be updated annually to best match circulating strains of the virus.
Moderna Stock Flashing Intriguing ‘Buy The Dip' Signal
Moderna (MRNA) stock made a name for itself during the height of the pandemic, trading as high as $497 five years ago in 2021. Now, shares of the drugmaker sit at $55.12, pivoting lower despite the Food and Drug Administration (FDA) approving the company's flu vaccine.
